

Brett William Stringer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9361235/publications.pdf>

Version: 2024-02-01

55
papers

2,167
citations

257357

24
h-index

233338

45
g-index

57
all docs

57
docs citations

57
times ranked

4433
citing authors

#	ARTICLE	IF	CITATIONS
1	STAT3 Enhances Sensitivity of Glioblastoma to Drug-Induced Autophagy-Dependent Cell Death. <i>Cancers</i> , 2022, 14, 339.	1.7	6
2	Long-term adherence of human brain cells in vitro is enhanced by charged amine-based plasma polymer coatings. <i>Stem Cell Reports</i> , 2022, 17, 489-506.	2.3	11
3	Transcriptomic Profiling of DNA Damage Response in Patient-Derived Glioblastoma Cells before and after Radiation and Temozolomide Treatment. <i>Cells</i> , 2022, 11, 1215.	1.8	5
4	Neutralisation of adeno-associated virus transduction by human vitreous humour. <i>Gene Therapy</i> , 2021, 28, 242-255.	2.3	6
5	Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth. <i>Cancers</i> , 2021, 13, 3773.	1.7	7
6	Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 41-53.	1.4	18
7	SRRM4 Expands the Repertoire of Circular RNAs by Regulating Microexon Inclusion. <i>Cells</i> , 2020, 9, 2488.	1.8	8
8	The Suitability of Glioblastoma Cell Lines as Models for Primary Glioblastoma Cell Metabolism. <i>Cancers</i> , 2020, 12, 3722.	1.7	10
9	MK2 Inhibition Induces p53-Dependent Senescence in Glioblastoma Cells. <i>Cancers</i> , 2020, 12, 654.	1.7	5
10	Constitutive CHK1 Expression Drives a pSTAT3-CIP2A Circuit that Promotes Glioblastoma Cell Survival and Growth. <i>Molecular Cancer Research</i> , 2020, 18, 709-722.	1.5	15
11	Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States Are Maintained in 3D Culture. <i>Cells</i> , 2020, 9, 267.	1.8	12
12	Lower Tubulin Expression in Glioblastoma Stem Cells Attenuates Efficacy of Microtubule-Targeting Agents. <i>ACS Pharmacology and Translational Science</i> , 2019, 2, 402-413.	2.5	14
13	The dystroglycan receptor maintains glioma stem cells in the vascular niche. <i>Acta Neuropathologica</i> , 2019, 138, 1033-1052.	3.9	19
14	Simultaneous targeting of DNA replication and homologous recombination in glioblastoma with a polyether ionophore. <i>Neuro-Oncology</i> , 2019, 22, 216-228.	0.6	8
15	A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. <i>Scientific Reports</i> , 2019, 9, 4902.	1.6	127
16	Expression and activity of the calcitonin receptor family in a sample of primary human high-grade gliomas. <i>BMC Cancer</i> , 2019, 19, 157.	1.1	15
17	Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. <i>Cancers</i> , 2019, 11, 190.	1.7	39
18	Novel dual-action prodrug triggers apoptosis in glioblastoma cells by releasing a glutathione quencher and lysine-specific histone demethylase 1A inhibitor. <i>Journal of Neurochemistry</i> , 2019, 149, 535-550.	2.1	11

#	ARTICLE	IF	CITATIONS
19	Extracellular Vesicles Released by Glioblastoma Cells Stimulate Normal Astrocytes to Acquire a Tumor-Supportive Phenotype Via p53 and MYC Signaling Pathways. <i>Molecular Neurobiology</i> , 2019, 56, 4566-4581.	1.9	77
20	Tropomyosin Tpm 2.1 loss induces glioblastoma spreading in soft brain-like environments. <i>Journal of Neuro-Oncology</i> , 2019, 141, 303-313.	1.4	10
21	Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. <i>Oncogene</i> , 2019, 38, 1151-1165.	2.6	21
22	A unique ¹⁹ F MRI agent for the tracking of non phagocytic cells <i>in vivo</i> . <i>Nanoscale</i> , 2018, 10, 8226-8239.	2.8	42
23	EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. <i>Cancers</i> , 2018, 10, 519.	1.7	25
24	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. <i>Pharmacological Research</i> , 2018, 134, 166-178.	3.1	8
25	Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2052-2070.	2.9	41
26	Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent <i>in vitro</i> in high-grade glioma cell lines derived from glioblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1217-1228.	2.0	15
27	Development and Biological Evaluation of a Photoactivatable Small Molecule Microtubule-Targeting Agent. <i>ACS Medicinal Chemistry Letters</i> , 2017, 8, 395-400.	1.3	28
28	EphA3 as a target for antibody immunotherapy in acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 1779-1787.	3.3	29
29	Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. <i>Oncotarget</i> , 2017, 8, 16605-16620.	0.8	30
30	Differential response of patient-derived primary glioblastoma cells to environmental stiffness. <i>Scientific Reports</i> , 2016, 6, 23353.	1.6	68
31	Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant. <i>British Journal of Cancer</i> , 2016, 114, 188-198.	2.9	16
32	Nuclear factor one B (<i>NFIB</i>) encodes a subtype-specific tumour suppressor in glioblastoma. <i>Oncotarget</i> , 2016, 7, 29306-29320.	0.8	34
33	Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. <i>Journal of Medical Radiation Sciences</i> , 2015, 62, 92-98.	0.8	35
34	Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. <i>Anatomy and Cell Biology</i> , 2015, 48, 25.	0.5	49
35	EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study. <i>Molecular Imaging</i> , 2015, 14, 7290.2015.00008.	0.7	24
36	The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. <i>Journal of Neuro-Oncology</i> , 2015, 122, 263-271.	1.4	44

#	ARTICLE	IF	CITATIONS
37	Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. <i>Biochemical Pharmacology</i> , 2015, 98, 587-601.	2.0	15
38	EphA2 as a Diagnostic Imaging Target in Glioblastoma: A Positron Emission Tomography/Magnetic Resonance Imaging Study. <i>Molecular Imaging</i> , 2015, 14, 385-99.	0.7	12
39	Eph receptors as therapeutic targets in glioblastoma. <i>British Journal of Cancer</i> , 2014, 111, 1255-1261.	2.9	62
40	Eph family co-expression patterns define unique clusters predictive of cancer phenotype. <i>Growth Factors</i> , 2014, 32, 254-264.	0.5	10
41	The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. <i>Tumor Biology</i> , 2014, 35, 1459-1465.	0.8	26
42	NFIB-Mediated Repression of the Epigenetic Factor <i>Ezh2</i> Regulates Cortical Development. <i>Journal of Neuroscience</i> , 2014, 34, 2921-2930.	1.7	70
43	Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells. <i>Molecular Oncology</i> , 2014, 8, 1603-1615.	2.1	61
44	Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. <i>Nature Neuroscience</i> , 2013, 16, 1373-1382.	7.1	408
45	EphA3 Maintains Tumorigenicity and Is a Therapeutic Target in Glioblastoma Multiforme. <i>Cancer Cell</i> , 2013, 23, 238-248.	7.7	193
46	A Metabolic Shift Favoring Sphingosine 1-Phosphate at the Expense of Ceramide Controls Glioblastoma Angiogenesis. <i>Journal of Biological Chemistry</i> , 2013, 288, 37355-37364.	1.6	90
47	Glioma Surgical Aspirate: A Viable Source of Tumor Tissue for Experimental Research. <i>Cancers</i> , 2013, 5, 357-371.	1.7	48
48	The Transcription Factor C/EBP- β Mediates Constitutive and LPS-Inducible Transcription of Murine SerpinB2. <i>PLoS ONE</i> , 2013, 8, e57855.	1.1	16
49	Regulation of the Human Plasminogen Activator Inhibitor Type 2 Gene. <i>Journal of Biological Chemistry</i> , 2012, 287, 10579-10589.	1.6	13
50	ELK4 neutralization sensitizes glioblastoma to apoptosis through downregulation of the anti-apoptotic protein Mcl-1. <i>Neuro-Oncology</i> , 2011, 13, 1202-1212.	0.6	32
51	Ephrin expression and function in cancer. <i>Future Oncology</i> , 2010, 6, 165-176.	1.1	19
52	The Glycosylphosphatidylinositol-Anchored Serine Protease PRSS21 (Testisin) Imparts Murine Epididymal Sperm Cell Maturation and Fertilizing Ability. <i>Biology of Reproduction</i> , 2009, 81, 921-932.	1.2	76
53	Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif. <i>Molecular and Cellular Biology</i> , 2003, 23, 6520-6532.	1.1	64
54	DNase I hypersensitive sites in the 5' flanking region of the human plasminogen activator inhibitor type 2 (PAI-2) gene are associated with basal and tumor necrosis factor-alpha-induced transcription in monocytes. <i>FEBS Journal</i> , 1998, 256, 550-559.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Southwestern blot mapping of potential regulatory proteins binding to the DNA encoding plasminogen activator inhibitor type 2. <i>Gene</i> , 1993, 134, 201-208.	1.0	17